Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used for
ever, no precedent for such long-term provision of TMP-SMX or any broad-spectrum antibiotic to such a large number of individuals in the community as is currently seen in HIV disease. If current prophylactic TMP-SMX regimens are resulting in the development of TMP-SMX-resistant bacteria, the drug's salutary prophylactic effect against P. carinii may need to be balanced against this increase in resistance. Although long-term TMP-SMX has been used in HIV disease for many years, little is known about the impact of this practice in terms of the development of resistant bacterial organisms. TMP-SMX use in HIV-infected patients has been implicated in the development of TMP-SMX-resistant Streptococcus pneumoniae [9] [10] [11] [12] [13] [14] [15] , but much less is known about the development of resistance in gram-negative bacteria, organisms for which TMP-SMX plays an important therapeutic role in the community, or resistance in Staphylococcus aureus, a common complicating organism in HIV disease. Furthermore, little is known about the impact of widespread long-term TMP-SMX use in HIV-infected patients on the resistance patterns in noninfected persons in the community.
The period from 1988 to 1995 at San Francisco General Hospital (SFGH) provided an ideal opportunity to study the effects of long-term TMP-SMX use in HIV-infected patients. After documenting that oral TMP-SMX was used uncommonly for pneumocystosis prophylaxis at the beginning of this period (aerosolized pentamidine was primarily prescribed) and that it subsequently rapidly became standard practice in the next few years, we conducted a serial cross-sectional study to determine trends in antimicrobial susceptibility to TMP-SMX and six other frequently used antibiotics in S. aureus and 7 common Enterobacteriaceae genera before and during times of widespread long-term TMP-SMX use in HIV disease. 
Materials and Methods
Population and sampling. SFGH is a 375-bed teaching hospital that is affiliated with the University of California, San Francisco, and is operated by the City and County of San Francisco. Between 1988 and 1995, the facility averaged 19,694 inpatient discharges and 324,337 outpatient visits each year, including an average of 1692 inpatient discharges and 44,891 outpatient visits for HIVrelated conditions between 1993 (when HIV-specific information became available) and 1995. All microbiologic testing at SFGH is done by one central clinical microbiology laboratory.
Beginning in January 1988, for each culture sample submitted to the clinical microbiology laboratory, the following data were entered into a computerized data storage system: the date and collection site (anatomic) of the sample, basic demographic information for the patient, the medical center unit or ward of origination for the sample, and microbiologic and antimicrobial susceptibility results. All inpatients and outpatients who had microbiologic specimens obtained between 1 January 1988 and 31 December 1995 that were culture-positive for S. aureus or 1 of 7 Enterobacteriaceae genera (Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella species, Proteus species, and Serratia species) and who had TMP-SMX antimicrobial susceptibility testing performed on their isolates were included in this study. All inpatients and outpatients who had 1 of the 8 genera above recovered from specimens submitted between 1979 and 1987 were also included in the study, but they are represented only in aggregate as the annual cumulative percentage of TMP-SMX-resistant strains for each genus. This is because individual culture records for this period are no longer available. Aggregatelevel data have been retrieved for 1979-1980 and 1982-1986 but are missing for 1981 and 1987.
Between 1988 and 1995, consecutive patient isolates collected from all anatomic sites were evaluated unless a patient had 11 isolate of a given genus obtained within a 30-day period. In such cases, the first isolate was used if all isolates tested within the 30 days had the same TMP-SMX susceptibility. If both a sensitive and resistant isolate were detected within 30 days in the same patient, both isolates were included. Cultures positive for the same genus and occurring 130 days apart were treated as separate isolates. In separate analyses, consecutive isolates from sterile sites only (blood, cerebrospinal fluid, peritoneum, joint, intraoperative surgical sites, and catheter-derived urine) were evaluated.
HIV infection status. The originating hospital unit or ward of a patient's culture was used as a proxy for the patient's HIV infection status. HIV-infected patients at SFGH are treated primarily in one outpatient and one inpatient unit. All patients in these two dedicated units are HIV-infected, but HIV-infected patients can be treated in other units when their infection is not yet recognized, when capacity is exceeded in the inpatient unit, or when they are treated as outpatients in the emergency room or other specialty clinics to which they have been referred. Prior to 1988, computerized data storage systems were not in place, and individual culture reports are no longer available. Hence, HIV infection status on patients prior to 1988 is not available.
Antimicrobial susceptibility. The SFGH clinical microbiology laboratory performed all antimicrobial susceptibility tests. Between 1979 and 1983, TMP-SMX susceptibility testing was done using Kirby-Bauer disk diffusion and BBL Sensi-Disks (Becton Dick- [16] . An MIC р2/38 mg/mL TMP-SMX was considered to demonstrate susceptibility, and an MIC 12/38 mg/mL TMP-SMX was considered to demonstrate resistance. From 1988 to 1995, susceptibility results for 6 other frequently used antibiotics (ampicillin, nafcillin, cefazolin, ceftriaxone, ciprofloxacin, and gentamicin) were also available from the computerized storage system, and NCCLS guidelines were again used to assess susceptibility [16] .
Prevalence of TMP-SMX use for PCP prophylaxis. Information on medication use for the large population of patients that had culture samples submitted to the clinical microbiology laboratory at SFGH was not recorded in any computerized data storage system. To estimate the prevalence of TMP-SMX use among HIVinfected subjects in San Francisco during this time, we used data from the San Francisco arm of the Pulmonary Complications of HIV Infection Study (PCHIS). PCHIS is fully described elsewhere [17] . In brief, PCHIS, which was designed to study the epidemiology of pulmonary disorders in HIV disease, was a six-center (San Francisco, Los Angeles, Chicago, Detroit, New York, and Newark) prospective cohort study of HIV-seropositive individuals recruited from local clinics. Subjects were enrolled in 1988 and were serially followed until 1994. At the San Francisco site, 253 participants were entered. To be included for period prevalence estimates of the use of TMP-SMX for PCP prophylaxis in San Francisco, San Francisco PCHIS subjects needed to meet a modified version of the 1989 and 1992 US Public Health Service Task Force criteria for PCP prophylaxis [18, 19] : a current or at least one prior CD4 lymphocyte count р200 cells/mm 3 or a prior history of PCP. At each interview, subjects were questioned about use of TMP-SMX, aerosolized pentamidine, dapsone, or any other drugs for PCP prophylaxis since the previous visit. To obtain the period prevalence of the use of TMP-SMX in a calendar year, any use of TMP-SMX by a subject within the year was considered.
Statistical analysis. Ninety-five percent confidence intervals based on a binomial distribution were estimated for the prevalence of TMP-SMX resistance in isolates obtained during a given time period [20] . Pearson's x 2 and Fisher's exact tests were used to assess associations between HIV infection status and TMP-SMX resistance and, among isolates from HIV-infected patients, the association between TMP-SMX resistance and resistance to one or more other antibiotics [21] . In these analyses, because individual patients might have contributed 11 isolate over time, only the first isolate was used for each person, to avoid violating statistical assumptions regarding independence. To determine differences in resistance over time in HIV-infected versus -noninfected patients, logistic regression models were formed, using year of collection and HIV status as main effect terms and as components of an interaction term between these variables. The P value associated with the interaction term was used to assess whether temporal changes in resistance (i.e., slope of resistance over time) differed between HIV-infected and -noninfected groups. Again, only initial patient isolates were used. All calculations were performed using Stata 5.0 [22] . 
Results
Between 1988 and 1995 at SFGH, 39,437 microbiologic cultures were positive for 1 of 8 bacterial species or genera (S. aureus or 1 of 7 Enterobacteriaceae). All but 119 isolates were tested for TMP-SMX susceptibility. After eliminating these and all cultures that had been performed within a 30-day period for a given patient and that had unchanged TMP-SMX susceptibility, 30,886 isolates were available for analysis from 19,514 patients. The median patient age was 36.2 years (interquartile range, 25.9-51.8), and 51.8% were female. Between 1979 and 1986 (excluding 1981, for which data are not available), 24,884 cultures yielding 1 of the 8 genera were available for analysis. Of the 55,770 cultures evaluated between 1979 and 1995, E. coli ( , 39%), S. aureus ( , 33%), n = 21,554 n = 18,227 and Klebsiella species ( , 9.9%) were the most common n = 5530 isolates. Figure 1 shows trends in TMP-SMX resistance for all 8 genera combined between 1979 and 1995. This includes the aggregate-level data from 1979 to 1986 and the individual patientlevel data from computerized records starting in 1988. TMP-SMX resistance was stable between 2.0% and 5.5% between 1979 and 1986, increased slightly to 7.2% in 1988, and then markedly increased, reaching 20.4% by 1995. The rapid increase in TMP-SMX resistance temporally coincided with an increase in prophylactic TMP-SMX use in San Francisco as measured in San Francisco PCHIS participants (figure 2). In 1989, when data first became available, oral TMP-SMX was used by 9% of San Francisco PCHIS participants who had indications for prophylaxis. Its use quickly became more prevalent in the early 1990s, reaching 47% in 1994.
Beginning in 1988, the SFGH hospital unit or ward of origination for each submitted specimen was recorded in a computerized database, and, hence, a proxy of HIV infection status could be assigned to all patients who had cultures submitted. Between 1988 and 1991, isolates obtained from patients on HIV and non-HIV units (not specifically dedicated to HIV-infected patients but may have contained them) had an equivalent and relatively stable prevalence of TMP-SMX resistance (figure 2). Subsequently, a large increase in the prevalence of TMP-SMX resistance occurred in isolates collected from the HIV units (from 6.3% in 1988 to 53.0% in 1995). TMP-SMX resistance also increased in isolates obtained from the non-HIV units, but to a much smaller degree (from 7.3% in 1988 to 17.7% in 1995; for temporal comparison with HIV units). When spec-P ! .001 imens were limited to sterile sites, there were 5377 cultures available for samples from 4312 patients. Although the smaller number of isolates resulted in less precise annual estimates of resistance, sterile-site isolates from HIV-infected patients again showed a much greater increase in TMP-SMX resistance from 1988 to 1995 than was seen in isolates collected from patients in non-HIV care units ( ). Further stratification of the P = .018 non-HIV care units showed that there were minor resistance differences in isolates derived from different units (e.g., pediatric patients typically had the highest prevalence of resistant isolates) but that from 1992 onward, isolates from patients on HIV units uniformly were more resistant (figure 3). When individual genera were considered, there was a statistically significant higher prevalence of TMP-SMX resistance in isolates from HIV-infected patients for each genus except Serratia species (table 1) . When isolates derived from HIV-infected patients were compared with those from noninfected patients, we found the most prominent temporal differences in TMP-SMX resistance in the 3 most commonly isolated bacteria (E. coli, S. aureus, and Klebsiella species). In HIV-infected patients, TMP-SMX resistance in S. aureus increased from 0% to 48% from 1988 to 1995 (figure 4), and resistance in E. coli increased from 24% to 74% (figure 5). In Klebsiella species, resistance was not present in HIV-infected patients in 1988 but increased to 36% by 1995 (full temporal progression not shown). For all 3 genera, the temporal increase seen in HIV-infected patients was significantly greater than that seen in noninfected patients ( for all three comparisons). When only isolates from P р .001 sterile sites were considered, similar trends were seen (data not shown). Analyses of the genera other than E. coli, S. aureus, and Klebsiella species showed no clear temporal increase in TMP-SMX resistance in isolates obtained from HIV-infected patients (data not shown).
Increases in resistance in isolates obtained from HIV-infected patients were not limited to TMP-SMX. As shown in figure 4 , from 1988 to 1995, S. aureus resistance to ciprofloxacin increased from 0% to 21%, resistance to nafcillin increased from 4% to 16%, and resistance to gentamicin increased from 0% to 14% (temporal progression not shown). The temporal increase for HIV-infected patients was significantly steeper than that seen in noninfected patients for ciprofloxacin ( ) and P = .024 gentamicin ( ) and borderline for nafcillin ( ). P = .033 P = .052 In E. coli, resistance to ampicillin among isolates from HIVinfected patients increased from 41% to 72%, and resistance to cefazolin increased from 0% to 14% (figure 5), although these increases were not significantly steeper than those seen in noninfected patients. No clinically significant changes occurred in resistance of E. coli to ceftriaxone, ciprofloxacin, or gentamicin in either HIV-infected or -noninfected patients.
To explore whether TMP-SMX use in HIV-infected patients may contribute to the emergence of multidrug resistance, the prevalence of resistance to one or more antibiotics other than TMP-SMX was compared between TMP-SMX-resistant and -susceptible isolates (table 2) . In E. coli, HIV-infected patients with TMP-SMX-resistant isolates were significantly more likely also to display ampicillin, cefazolin, and gentamicin resistance and had a greater prevalence of ampicillin-cefazolin or ampicillin-gentamicin dual resistance. In S. aureus, those with TMP-SMX-resistant isolates were more likely also to have nafcillin, ciprofloxacin, and gentamicin resistance and were more likely to exhibit nafcillin-ciprofloxacin-gentamicin multidrug resistance.
Discussion
In San Francisco, after a period from 1979 through the late 1980s, when bacterial resistance to TMP-SMX was stable and limited (!10% overall in 8 common isolates), TMP-SMX resistance increased markedly in the early 1990s and was most prominent in HIV-infected patients. Among HIV-infected patients, TMP-SMX resistance was associated with multidrug resistance in several genera. Although our data cannot directly establish long-term oral TMP-SMX use in HIV-infected patients as the cause of the increased TMP-SMX resistance, this is likely the case, since the period from 1988 to 1995 is when long-term oral TMP-SMX use for PCP prophylaxis increased substantially in San Francisco. In 1994, it was estimated that 7000 persons were living with AIDS in San Francisco [23] . Assuming that the 47% prevalence of prophylactic TMP-SMX use found in this study can be applied to the entire AIDS population, then an estimated 3290 individuals were using this potent broad-spectrum antibacterial agent on a long-term basis in a geographically confined community.
TMP-SMX resistance has developed in other populations where oral TMP-SMX has been used prophylactically. For example, when used in neutropenic oncologic patients, prophylactic TMP-SMX resulted in the development of TMP-SMX-resistant gram-negative bacilli in the patients' flora [8, [24] [25] [26] [27] [28] and of TMP-SMX-resistant clinical infections [7, 8] . The duration of TMP-SMX use in neutropenic patients is, however, much shorter that in HIV disease, and in most urban areas, the number of such individuals is much smaller than the number of persons with HIV infection. Hence, the neutropenic popu- Prescription of long-term oral TMP-SMX for PCP prophylaxis in HIV disease became a US Public Health Service recommendation in 1989 [18] , but there has been little work describing the impact of this practice on the emergence of bacterial TMP-SMX resistance. Most work has focused on the development of TMP-SMX resistance in S. pneumoniae [11, 13] . Ours is the first study to document resistance in a wide variety of gram-negative species and in S. aureus. For both E. coli and S. aureus, our data not only provide another example of the emergence of isolated antibiotic resistance as a result of selective pressure from use of that antibiotic but also suggest the selection for multidrug-resistant isolates, which carry graver clinical consequences, from use of a single antibiotic.
There are several limitations of this study. Because some HIVinfected patients were likely included in the non-HIV unit grouping, the observed association between HIV infection and the development of TMP-SMX resistance is likely an underestimate of the true association. Because HIV infection was used as a proxy for long-term TMP-SMX use, an important percentage of individuals from the HIV care units likely did not yet have an indication for PCP prophylaxis and were not using the agent. Thus, the association seen in this study between HIV infection and the development of TMP-SMX resistance may be substantially underestimating the true association between long-term TMP-SMX use in HIV-infected patients and the development of TMP-SMX resistance.
As not all HIV-infected patients were using TMP-SMX, we cannot with certainty link the resistant isolates to those receiving TMP-SMX (which would substantiate the association between TMP-SMX use and emergence of resistance) nor exclude that the resistant isolates were occurring in those not taking TMP-SMX (which would not support the hypothesized association). Thus, it is conceivable that another factor besides TMP-SMX use that is associated with HIV disease is responsible for the increase in TMP-SMX resistance. Specifically, because resistance to several other antibiotics also increased during this time, antibiotic use other than TMP-SMX in HIV-infected patients could be selecting for resistance to several different antibiotics (including TMP-SMX). We view this as unlikely because the magnitude of temporal increase in TMP-SMX resistance was so much larger than any other common antibiotic and because TMP-SMX was by far the most commonly used antibiotic among HIV-infected patients.
Assuming TMP-SMX use is responsible for the observed increase in the percentage of isolates resistant to TMP-SMX, there are two possible interpretations for the findings. One is that prophylactic TMP-SMX use in HIV disease results in an increased absolute incidence of TMP-SMX-resistant infections. If TMP-SMX use has no impact on the overall incidence of bacterial infections in HIV disease, then when HIV-infected patients have bacterial infections, their TMP-SMX use selects for TMP-SMX-resistant strains and an increased percentage and increased absolute incidence of TMP-SMX-resistant infections is seen (relative to that for non-TMP-SMX-using patients). Alternatively, if the incidence of TMP-SMX-susceptible bacterial infections in HIV disease is decreased by prophylactic TMP-SMX use, prophylactic TMP-SMX use may only alter the percentage of resistant isolates but not actually increase the absolute incidence. There is evidence in other studies that prophylactic TMP-SMX in HIV disease can decrease the overall incidence of bacterial infections [1, 29] , but because we do not have reliable data on rates of bacterial infection in HIV-infected patients during this time at SFGH, it is not possible to distinguish between the two interpretations.
In San Francisco, TMP-SMX is no longer a prudent option for empiric antibacterial therapy in HIV-infected patients. It likewise has limited utility for definitive treatment. Moreover, because multidrug resistance was associated with TMP-SMX resistance, prophylactic TMP-SMX use may select for multiresistant bacteria that further complicate therapeutic options. The implications for individuals not infected with HIV are less certain. Because we cannot quantitate the extent to which the increase in TMP-SMX resistance in non-HIV units is explained by HIV-infected patients being interspersed on these units, we cannot determine the extent to which the widespread long-term use of TMP-SMX in HIV-infected persons influences the flora of others in the community. Resolving this question is critical if recent evidence touting the efficacy of TMP-SMX prophylaxis in decreasing morbidity and mortality in HIV disease in developing countries [30, 31] translates into the public healthscale administration of TMP-SMX in areas endemic for the disease.
